IL2 and renal cell carcinoma: However, only two cytokines have received FDA (Federal Drug Administration) approval as single anti-cancer agents so far: IFN-alpha for Stage III melanoma adjuvant therapy and IL-2 for metastatic melanoma and RCC [125–127].